Theranostics: integrating molecular imaging and targeted therapy for precision medicine across oncology and beyond

Sanjeyan N.; Yuvaraj C.; Naveen Kumar S.; Balakrishnan S.; Suban M.

doi:10.18203/2320-6012.ijrms20263578

Authors

Sanjeyan N. Department of Pharmacy Practice, JKKMMRF’s Annai JKK Sampoorani Ammal College of Pharmacy, Komarapalayam, Namakkal, Tamil Nadu, India
Yuvaraj C. JKKMMRF’s Annai JKK Sampoorani Ammal College of Pharmacy, Komarapalayam, Namakkal, Tamil Nadu, India
Naveen Kumar S. JKKMMRF’s Annai JKK Sampoorani Ammal College of Pharmacy, Komarapalayam, Namakkal, Tamil Nadu, India
Balakrishnan S. JKKMMRF’s Annai JKK Sampoorani Ammal College of Pharmacy, Komarapalayam, Namakkal, Tamil Nadu, India
Suban M. JKKMMRF’s Annai JKK Sampoorani Ammal College of Pharmacy, Komarapalayam, Namakkal, Tamil Nadu, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20263578

Keywords:

Theranostics, Precision medicine, Radiotheranostics, Nanotheranostics, Phototheranostics, PET imaging

Abstract

To review the principles, mechanisms, clinical applications, safety considerations, challenges and future perspectives of theranostics. Literature from peer-reviewed journals, clinical trials and authoritative sources was reviewed. Theranostics integrates molecular imaging and targeted therapy, demonstrating significant benefits in neuroendocrine tumors, prostate cancer, lymphoma and emerging non-oncologic diseases. Theranostics represents a cornerstone of precision medicine and is expected to expand further with advances in artificial intelligence, nanotechnology and novel radiopharmaceuticals.

References

Funkhouser J. A brief introduction to the industrial universe. PharmaNetics. 1998.

Hertz S, Roberts A, Salter WT. Radioactive iodine as an indicator in thyroid physiology. IV. The metabolism of iodine in Graves' disease. J Clin Invest. 1942;21(1):25-9.

Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. JAMA. 1946;132(14):838-47.

Ehrhardt JD Jr, Güleç S. A review of the history of radioactive iodine theranostics: the origin of nuclear oncology. Mol Imaging Radionucl Ther. 2020;29(3):88-97.

Goldsmith SJ. History of 131I therapy. J Nucl Med. 2012;53(11):1839-40.

Bodei L, Iagaru A, Schmidt A, et al. Theranostics in oncology: from molecular imaging to precision medicine. Eur J Nucl Med Mol Imaging. 2020;47Suppl 1:1-4

Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. Bioconjug Chem. 2011;22(10):1879-903.

Lameijer MC, Dierckx RAJO, de Vries EGE, et al. Molecular nuclear medicine: the future of molecular imaging and targeted therapy. Lancet Oncol. 2020;21(3):e130-43. (not matching)

Vikram R, Johnson CB, Kwee TC. Theranostics: a primer for medical students and residents. SeminNucl Med. 2025;55(2):245-56. (Author name not matching)

Gorin MA, Rowe SP, Baras AS, et al. Prospective evaluation of 68Ga-PSMA PET/CT for preoperative staging of intermediate- to high-risk prostate cancer. Eur Urol. 2017;71(3):384-91.

Weber WA, Czernin J. From nuclear medicine to theranostics: the long road to precision oncology. J Nucl Med. 2021;62Suppl 1:17S-22S.

Herrmann K, Larson SM, Weber WA. Theranostics: an overview from concept to clinical implementation. J Nucl Med. 2021;62Suppl 1:1S-6S.

Pascual TNB, et al. Guiding principles on the education and practice of theranostics. Eur J Nucl Med Mol Imaging. 2024;51(7):1456-1467(page no , volume not matching.Pascual TNB, Paez D, Iagaru A, Gnanasegaran G, Lee ST, Sathekge M, et al. Guiding principles on the education and practice of theranostics. Eur J Nucl Med Mol Imaging. 2024;51(8):2320-2331.

Crown Bioscience. Theranostic strategies: dual-function agents for imaging and therapy in precision medicine Crown Bioscience. Available from: https://blog.crownbio.com/theranostics-imaging-therapy-precision-medicine, Accessed on. 10 Jun 2026 (same as reference 19)

Sedlack AJH, Meyer C, Mench A, Winters C, Barbon D, Obrzut S, et al. Essentials of theranostics: a guide for physicians and medical physicists. Radiographics. 2024;44(1):e230097.

University of Chicago Medicine. Theranostics [Internet]. Chicago: University of Chicago Medicine; 2022 Available from: https://www.uchicagomedicine.org/cancer/types-treatments/theranostics. Accessed on 27 December 2025

Icon Cancer Centre. Theranostics cancer treatment: what is theranostics? FAQs [Internet]. Icon Cancer Centre; 2022 Available from: https://iconcancercentre.co.uk/treatments/theranostics/. Accessed on 27 December 2025.

Burkett BJ, Bartlett DJ, McGarrah PW, Lewis AR, Johnson DR, Berberoğlu K, et al. A review of theranostics: perspectives on emerging approaches and clinical advancements. Radiol Imaging Cancer. 2023;5(4):e220157.

Crown Bioscience. Theranostic strategies: dual-function agents for imaging and therapy in precision medicine [Internet]. Crown Bioscience; 2025 [cited 2025 Dec 27]. Available from: https://blog.crownbio.com/theranostics-imaging-therapy-precision-medicine (same as reference 14)

RLT Institute-Novartis. Theranostic applications of radiation. Novartis; 2011 Available from: https://www.rltinstitute.novartis.com/foundations-of-theranostics/radiation-science-fundamentals/theranostic-applications/.Accessed on 27-Dec-2025.

Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. Bioconjug Chem. 2011;22(10):1879-903.

Hapuarachchige S. Theranostic pretargeting drug delivery and imaging platforms in cancer precision medicine. Front Oncol. 2020;10:1131.

Pryma DA, et al. Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with metastatic pheochromocytoma and paraganglioma: a multicenter experience. J Nucl Med. 2018;59(12):1929-1935.(Not matcing) Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L, et al. Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J Nucl Med. 2019;60(5):623-30.

Vegt E, et al. Peptide receptor radionuclide therapy with 90Y-DOTATATE/90Y-DOTATOC in patients with advanced neuroendocrine tumors. World J Gastroenterol. 2013;19(10):1524-1532.

Choy JS, et al. Incidental uptake of In-111 ibritumomabtiuxetan in surgically removed tissue. Open Med Sci J. 2010;4:132-134. (authors not matching)( Incidental Uptake of In-111 Ibritumomab Tiuxetan in Surgically Treated Fracture) is coming

Sartor O, et al. Samarium-153-EDTMP with or without external beam radiotherapy for bone metastases. Oncotarget. 2016;7(32):52125-52138( title not matching with volume, page no)

Eiber M, et al. Prostate cancer diagnostic performance of 68Ga-PSMA-11 PET/CT. ClinNucl Med. 2023;48(5):365-371. (not found)

Assadi M. Emerging preclinical and clinical applications of theranostics. SeminNucl Med. 2021;51(4):297-304.

Premierscience. Theranostics 2.0: the expanding clinical applications of theranostics. Pak J Biol Sci. 2025;28(10):1047-1058 (provide doi)

Mathews Open Access Journals. Emerging trends and innovations in theranostics for nuclear medicine [Internet]. Mathews Open Access Journals; 2024 [cited 2025 Dec 27]. Available from: https://www.mathewsopenaccess.com/full-text/revolutionizing-diagnostic-precision-emerging-trends-and-innovations-in-theranostics (give proper reference, specific book)

Cicone F, Gnesin S, Santo G, Stokke C, Bartolomei M, Cascini GL, et al. Do we need dosimetry for the optimization of theranostics in CNS tumors? Neuro Oncol. 2024;26(Suppl 9):S242-S258.

Bednarz B, et al. Theranostics and patient-specific dosimetry. Radiol Imaging Cancer. 2023;5(4):e220157.

Miller C, Rousseau J, Ramogida CF. Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs. Theranostics. 2022;12(1):232-259.

Mahajan A, et al. Theranostics in developing countries: addressing challenges and opportunities. Radiol Imaging Cancer. 2023;5(5):e230032. (Author not matching, volume not matching

Brink A, et al. Global challenges in the provision of theranostic services. Radiol Imaging Cancer. 2025;7(4):e240156. (volume not matching)

Currie G. Molecular theranostics: principles, challenges and controversies. J Med Radiat Sci. 2025;72(1):22-30. (not exactly found)

Pathmaraj K, Lee ST. Approaches to conducting clinical trials in theranostics. ClinTranslRadiatOncol. 2025;48:100110.

Trpezanovski M, et al. Personalized dosimetry in theranostic treatment of pediatric patients. ClinNucl Med. 2025;50(10):e605-e610 (not exactly founf, title is different, volume, issue)

Singh D, et al. Smart nanomaterials in cancer theranostics: challenges and opportunities. ACS Omega. 2023;8(15):13547-13560. (author, page numbers are different)

Gomes Marin JF, et al. Theranostics in nuclear medicine: emerging and re-emerging integrated imaging and therapies in the era of precision oncology. RadioGraphics. 2020;40(7):200021. (issue , page number different)

Bilgin GB, et al. Current and future directions in theranostics. Lancet Oncol. 2025;26(10):e458-67.

Pathmaraj K, Lee ST. Multidisciplinary Perspectives of Clinical Trials in Theranostics. World J Nucl Med. 2025;24(3):214-20.

Bilgin GB, et al. Current and future directions in theranostics. Eur J Nucl Med Mol Imaging. 2025;52(7):1234-45.

Theranostics [Internet]. Singapore: Ivyspring International Publisher; 2025 [cited 2025 Dec 27]. Available from: https://www.thno.org (title , authors, proper is missing).